New combo shows promise in battle against blood cancer
NCT ID NCT06068621
First seen Jan 21, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tested whether a combination of the drug venetoclax plus a chemotherapy regimen called CACAG works better than the standard "3+7" chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). The trial enrolled 200 patients aged 14 to 75. The main goal was to see how many patients achieved complete remission or near-complete remission after one treatment cycle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.